Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALAPRO 1 talazoparib monotherapy in DDR-positive metastatic castration-resistant prostate cancer
NL-OMON53009Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in prostate cancer (PCa), sponsored by Pfizer. Primary endpoint: Best objective response rate. Started Feb 2018; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON53009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53009.